跳至主要内容
临床试验/NCT00206622
NCT00206622已完成4 期

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing a 2.2mg 17 Beta-Estradiol/0.69mg Levonorgestrel Combination Transdermal Patch, and a 1mg 17 Beta-Estradiol Transdermal Patch With a Placebo Patch in Postmenopausal Women to Determine the Lowest Effective Dose of Estradiol for the Relief of Moderate to Severe Hot Flushes

Bayer0 个研究点目标入组 425 人开始时间: 2004年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Bayer
入组人数
425
主要终点
Lowest effective dose in decreasing the frequency and severity of hot flushes

研究概览

简要总结

To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women

详细描述

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Menopause
  • Reporting a minimum of 7 moderate to severe hot flushes per day for at least 1 week (7 consecutive days), or a minimum of 50 moderate to severe hot flushes per week for at least 1 week (7 consecutive days)

排除标准

  • Hormonal treatment
  • Contraindication to estrogen/progestogen therapy

研究组 & 干预措施

Arm 1

Active Comparator

干预措施: Climara PRO (Estradiol / Levonorgestrel transdermal) (Drug)

Arm 2

Active Comparator

干预措施: Menostar (Estradiol transdermal) (Drug)

Arm 3

Placebo Comparator

干预措施: Placebo transdermal (Drug)

结局指标

主要结局

Lowest effective dose in decreasing the frequency and severity of hot flushes

次要结局

  • Other symptoms related to menopause

研究者

发起方
Bayer
申办方类型
Industry

相似试验

Efficacy and Safety Study in Postmenopausal Women to... | 临床试验